Genprex Financials

GNPX Stock  USD 0.36  0.01  2.86%   
Based on the key measurements obtained from Genprex's financial statements, Genprex is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Genprex's Common Stock Total Equity is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 15.4 M in 2025, whereas Property Plant And Equipment Net is likely to drop 8,586 in 2025. Key indicators impacting Genprex's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.01140.012
Notably Down
Slightly volatile
Current Ratio1.982.08
Notably Down
Very volatile
The financial analysis of Genprex is a critical element in measuring its lifeblood. Investors should not minimize Genprex's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(26.39 Million)

  
Understanding current and past Genprex Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Genprex's financial statements are interrelated, with each one affecting the others. For example, an increase in Genprex's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Genprex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genprex. Check Genprex's Beneish M Score to see the likelihood of Genprex's management manipulating its earnings.

Genprex Stock Summary

Genprex competes with Reviva Pharmaceuticals, Greenwich Lifesciences, Cognition Therapeutics, Eyenovia, and Transcode Therapeutics. Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Genprex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS3724461047
CUSIP372446104 372446203
LocationTexas; U.S.A
Business Address3300 Bee Cave
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.genprex.com
Phone877 774 4679
CurrencyUSD - US Dollar

Genprex Key Financial Ratios

Genprex Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets31.4M42.9M25.1M10.7M12.3M15.4M
Other Current Liab257.8K612.1K2.4M1.9M2.1M2.2M
Net Tangible Assets8.5M2.5M30.3M40.6M46.7M49.1M
Net Debt(27.3M)(38.6M)(21.0M)(6.7M)(6.1M)(6.4M)
Retained Earnings(58.4M)(78.0M)(102.8M)(133.7M)(120.3M)(114.3M)
Accounts Payable193.0K973.2K442.9K1.4M1.6M1.7M
Cash27.3M38.6M21.0M6.7M7.7M13.0M
Other Assets21.7K612.4K0.01.00.90.86
Other Current Assets384.7K1.0M484.2K794.1K913.3K958.9K
Total Liab450.7K1.6M2.8M3.3M3.7M3.9M
Total Current Assets30.7M39.1M21.5M7.5M8.7M13.8M
Intangible Assets601.6K642.4K702.1K773.5K889.5K523.9K
Common Stock43.1K47.9K48.1K1.5K1.7K1.6K
Net Invested Capital30.9M41.3M22.3M7.4M8.5M8.1M
Net Working Capital30.3M37.6M18.7M4.3M4.9M4.7M
Capital Stock43.1K47.9K48.1K1.5K1.7K1.6K

Genprex Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Genprex. It measures of how well Genprex is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Genprex brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Genprex had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Genprex has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
202020212022202320242025 (projected)
Change In Cash25.3M11.3M(17.7M)(14.2M)(12.8M)(12.2M)
Free Cash Flow(16.3M)(14.4M)(17.8M)(24.8M)(22.3M)(21.2M)
Depreciation22.8K22.5K25.6K15.0K17.3K13.6K
Capital Expenditures2.3M83.8K59.7K71.4K82.1K78.0K
Net Income(17.9M)(19.6M)(23.7M)(30.9M)(27.8M)(26.4M)
End Period Cash Flow27.3M38.6M21.0M6.7M7.7M13.0M
Change To Netincome3.5M4.2M4.3M4.7M5.4M3.7M
Investments(2.3M)(83.8K)97.7K76.1K87.5K91.9K
Other Non Cash Items4.5M4.6M(1.0)989.5K1.1M996.4K

Genprex Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Genprex's current stock value. Our valuation model uses many indicators to compare Genprex value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genprex competition to find correlations between indicators driving Genprex's intrinsic value. More Info.
Genprex is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Genprex's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genprex's earnings, one of the primary drivers of an investment's value.

Genprex Systematic Risk

Genprex's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Genprex volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Genprex correlated with the market. If Beta is less than 0 Genprex generally moves in the opposite direction as compared to the market. If Genprex Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genprex is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genprex is generally in the same direction as the market. If Beta > 1 Genprex moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Genprex Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Genprex's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Genprex growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0545

At this time, Genprex's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Genprex March 17, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Genprex help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genprex. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genprex based on widely used predictive technical indicators. In general, we focus on analyzing Genprex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genprex's daily price indicators and compare them against related drivers.

Additional Tools for Genprex Stock Analysis

When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.